TMO Research Update — August 28, 2026
Updated Thesis
Thermo Fisher Scientific is a global leader in scientific services, offering life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services. The company benefits from a diversified portfolio, strong brand recognition, and a wide customer base across pharma, biotech, academic, and government sectors. In the most recent quarter, revenue grew 10.5% and earnings grew 7.4% year-over-year, reflecting solid demand.
The investment grade as of this refresh is B — solid business quality. High-tier business, fair valuation with upside to blended fair value
Grade Change
In this research cycle, the investment grade for Thermo Fisher Scientific Inc. moved from A to B. High-tier business, fair valuation with upside to blended fair value
Key Metrics at a Glance
- Revenue growth: +10.5% year over year
- Net margin: 15.1%
- Fair value upside: +31.9% to our estimate of $832
Current price: $630.70
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Thermo Fisher Scientific Inc. remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full TMO research →](/stocks/TMO)